Personalis (NASDAQ:PSNL) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Personalis (NASDAQ:PSNL) from a hold rating to a sell rating in a research note released on Saturday morning.

Several other brokerages have also commented on PSNL. BTIG Research increased their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Morgan Stanley raised their price target on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Lake Street Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Personalis in a research note on Wednesday, November 5th. Finally, Guggenheim boosted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.14.

Personalis Price Performance

Personalis stock opened at $9.06 on Friday. Personalis has a 1-year low of $2.83 and a 1-year high of $11.50. The business has a fifty day moving average price of $8.83 and a 200-day moving average price of $7.98. The stock has a market capitalization of $804.53 million, a price-to-earnings ratio of -9.96 and a beta of 1.98.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative return on equity of 42.81% and a negative net margin of 116.69%. On average, equities research analysts anticipate that Personalis will post -1.4 earnings per share for the current fiscal year.

Institutional Trading of Personalis

A number of hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC grew its position in shares of Personalis by 4.5% during the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after acquiring an additional 168,143 shares during the period. Aberdeen Group plc boosted its position in Personalis by 35.7% during the third quarter. Aberdeen Group plc now owns 2,387,947 shares of the company’s stock worth $15,569,000 after purchasing an additional 628,450 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Personalis in the second quarter valued at approximately $451,000. Geode Capital Management LLC grew its holdings in Personalis by 165.6% in the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after purchasing an additional 851,422 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in shares of Personalis in the second quarter valued at approximately $89,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Key Headlines Impacting Personalis

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.